PMID- 25524371
OWN - NLM
STAT- MEDLINE
DCOM- 20160519
LR  - 20220408
IS  - 1873-4286 (Electronic)
IS  - 1381-6128 (Linking)
VI  - 21
IP  - 11
DP  - 2015
TI  - Influence of bariatric surgery on the expression of nesfatin-1 in rats with type 
      2 diabetes mellitus.
PG  - 1464-71
AB  - OBJECTIVE: Bariatric surgery has been reported to be very effective in the 
      remission of type 2 diabetes mellitus (T2DM). However, the mechanism is still 
      under debate. Nesfatin-1, a recently discovered anorexigenic neuropeptide, was 
      reported to be very important in glucose metabolism and regulating food intake. 
      In this study, the effects of bariatric surgery on the expression and regulation 
      of nesfatin-1 were discussed. METHODS: T2DM was induced in SD rats by a diet high 
      in sugar and fat plus a low dose of streptozotocin (STZ) (25 mg/kg) injection. 
      Bariatric surgeries, including Roux-En-Y Gastric Bypass (RYGB) and sleeve 
      gastrectomy (SG), were performed on these rats. Two months after the surgery, the 
      plasma nesfatin-1 level and the expression of nesfatin-1 in different organs of 
      the rats were tested. Next, in vivo administration of nesfatin-1 after surgery 
      was performed to investigate the role of nesfatin-1 in bariatric surgery. 
      RESULTS: Both RYGB and SG could reduce the weight of the rats. However, only RYGB 
      had significant effects on the blood glucose level. Neither surgeries seemed to 
      affect the blood concentration of insulin. However, RYGB significantly improved 
      insulin sensitivity. Expression of nesfatin-1 in the plasma and relative organs 
      decreased in T2DM rats and rose again after RYGB; however, this pattern did not 
      occur in SG. Injection of nesfatin-1 after SG significantly improved insulin 
      resistance and reduced blood glucose levels. CONCLUSIONS: Nesfatin-1 may improve 
      insulin sensitivity in T2DM rats and thus plays a very important role in the 
      remission of T2DM after RYGB. This neuropeptide could be a new target for 
      directing future improvements in the bariatric surgical process.
FAU - Xia, Zefeng
AU  - Xia Z
FAU - Wang, Geng
AU  - Wang G
FAU - Li, Huiqing
AU  - Li H
FAU - Hu, Chaojie
AU  - Hu C
FAU - Wang, Qingbo
AU  - Wang Q
FAU - Li, Anshu
AU  - Li A
FAU - Zhao, Ende
AU  - Zhao E
FAU - Shuai, Xiaoming
AU  - Shuai X
FAU - Wang, Jiliang
AU  - Wang J
FAU - Cai, Kailin
AU  - Cai K
FAU - Tao, Kaixiong
AU  - Tao K
FAU - Wang, Guobin
AU  - Wang G
AD  - Department of Surgery, Union Hospital, Tongji Medical College, Huazhong 
      University of Science and Technology. wangguobinuh@126.com.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United Arab Emirates
TA  - Curr Pharm Des
JT  - Current pharmaceutical design
JID - 9602487
RN  - 0 (Blood Glucose)
RN  - 0 (Calcium-Binding Proteins)
RN  - 0 (DNA-Binding Proteins)
RN  - 0 (Nerve Tissue Proteins)
RN  - 0 (Nucb1 protein, rat)
RN  - 0 (Nucleobindins)
RN  - 5W494URQ81 (Streptozocin)
SB  - IM
MH  - Animals
MH  - Blood Glucose
MH  - Calcium-Binding Proteins/administration & dosage/blood/*metabolism
MH  - DNA-Binding Proteins/administration & dosage/blood/*metabolism
MH  - Diabetes Mellitus, Experimental/surgery
MH  - Diabetes Mellitus, Type 2/*surgery
MH  - Gastrectomy/*methods
MH  - Gastric Bypass/*methods
MH  - Insulin Resistance/physiology
MH  - Male
MH  - Nerve Tissue Proteins/administration & dosage/blood/*metabolism
MH  - Nucleobindins
MH  - Rats
MH  - Rats, Sprague-Dawley
MH  - Streptozocin
EDAT- 2014/12/20 06:00
MHDA- 2016/05/20 06:00
CRDT- 2014/12/20 06:00
PHST- 2014/11/03 00:00 [received]
PHST- 2014/12/16 00:00 [accepted]
PHST- 2014/12/20 06:00 [entrez]
PHST- 2014/12/20 06:00 [pubmed]
PHST- 2016/05/20 06:00 [medline]
AID - CPD-EPUB-64106 [pii]
AID - 10.2174/1381612821666141219125527 [doi]
PST - ppublish
SO  - Curr Pharm Des. 2015;21(11):1464-71. doi: 10.2174/1381612821666141219125527.